Literature DB >> 8120385

Characterization of the human CD27 ligand, a novel member of the TNF gene family.

R Q Hintzen1, S M Lens, M P Beckmann, R G Goodwin, D Lynch, R A van Lier.   

Abstract

CD27 is a lymphocyte-specific member of the TNF/NGF-R family that is highly induced on T cells after TCR stimulation, primarily on lymphocytes belonging to the unprimed CD45RA+ subset. However, after prolonged activation both in vivo and in vitro, CD27 expression is gradually switched off. In search of physiologic signals that influence CD27 expression, we found that B cell lines can mediate down-regulation of CD27 surface expression on activated T cells via direct cell-to-cell contact and that preincubation of activated T cells with CD27 mAbs prevented this modulation. Based on these observations, we hypothesized that a ligand for CD27L is expressed on B cell lines and that ligand interaction would result in down-modulation of the molecule from the T cell surface. To identify this putative CD27L, mAbs were raised against the Burkitt cell line Ramos and screened for their ability to block down-modulation of CD27 on activated T cells. Using this approach, we isolated a mAb, designated 2F2, that inhibits CD27 down-regulation in a dose-dependent manner. We demonstrate that this mAb recognizes CD27L as it 1) reacted to mouse fibroblasts expressing the recently cloned CD27L, a novel surface-expressed member of the TNF gene family, and 2) prevented binding of a soluble CD27-Fc construct to a CD27L expressing cell line. Down-regulation of CD27 from the T cell surface by recombinant CD27L was shown to be at least partially caused by release of soluble CD27. The 2F2 mAb enabled us to begin to analyze the biochemical properties, tissue distribution, and function of the CD27L on human cells. From cell lysates of 125I surface-labeled Burkitt cells a complex immunoprecipitation pattern with dominant bands of 29, 55, and 122 to 127 kDa was obtained using the 2F2 mAb. Phenotypical analyses showed that freshly isolated lymphocytes lacked CD27L expression, but that expression of the molecule could be induced after in vitro stimulation of T and B cells. No expression was found on cells of the myeloid lineage or on endothelial cells. Finally, blocking of naturally expressed CD27L by the 2F2 mAb exerted a potent inhibitory effect on the proliferation of T cells in response to allogeneic B cells and PHA. The data presented in this paper identify CD27 and its ligand as potentially important structures involved in cellular interactions between T and B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120385

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  CD70 expression patterns in renal cell carcinoma.

Authors:  Lucia B Jilaveanu; Joshua Sznol; Saadia A Aziz; Dylan Duchen; Harriet M Kluger; Robert L Camp
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

2.  Reduced CD27 expression on antigen-specific CD4+ T cells correlates with persistent active tuberculosis.

Authors:  Jing Jiang; Xianyuan Wang; Xinjing Wang; Zhihong Cao; Yanhua Liu; Mei Dong; Aihua Tong; Xiaoxing Cheng
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

3.  Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells.

Authors:  Douglas V Dolfi; Alina C Boesteanu; Constantinos Petrovas; Dong Xia; Eric A Butz; Peter D Katsikis
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

Review 4.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

5.  Epigenetic modifications induced by Blimp-1 Regulate CD8⁺ T cell memory progression during acute virus infection.

Authors:  Hyun Mu Shin; Varun Kapoor; Tianxia Guan; Susan M Kaech; Raymond M Welsh; Leslie J Berg
Journal:  Immunity       Date:  2013-10-10       Impact factor: 31.745

6.  Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells.

Authors:  S M Lens; P A Baars; B Hooibrink; M H van Oers; R A van Lier
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

7.  Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.

Authors:  Kazue Arimoto-Miyamoto; Norimitsu Kadowaki; Toshio Kitawaki; Satoshi Iwata; Chikao Morimoto; Takashi Uchiyama
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

8.  Direct B/B-cell interactions in immunoglobulin synthesis.

Authors:  K Shinozaki; K Yasui; K Agematsu
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

9.  Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Authors:  Drew Pratt; Stefania Pittaluga; Maryknoll Palisoc; Patricia Fetsch; Liqiang Xi; Mark Raffeld; Mark R Gilbert; Martha Quezado
Journal:  J Neuropathol Exp Neurol       Date:  2017-08-01       Impact factor: 3.685

10.  Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Authors:  M C Ryan; H Kostner; K A Gordon; S Duniho; M K Sutherland; C Yu; K M Kim; A Nesterova; M Anderson; J A McEarchern; C-L Law; L M Smith
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.